Kestra Private Wealth Services LLC Has $8.36 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Kestra Private Wealth Services LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 290,204 shares of the biopharmaceutical company’s stock after purchasing an additional 8,322 shares during the period. Kestra Private Wealth Services LLC’s holdings in Pfizer were worth $8,355,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PFE. Bfsg LLC boosted its holdings in shares of Pfizer by 5.9% during the 3rd quarter. Bfsg LLC now owns 168,804 shares of the biopharmaceutical company’s stock worth $5,599,000 after buying an additional 9,442 shares during the period. Schmidt P J Investment Management Inc. boosted its holdings in shares of Pfizer by 7.0% during the 3rd quarter. Schmidt P J Investment Management Inc. now owns 10,286 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 677 shares during the period. Ascent Wealth Partners LLC boosted its holdings in shares of Pfizer by 2.5% during the 3rd quarter. Ascent Wealth Partners LLC now owns 42,699 shares of the biopharmaceutical company’s stock worth $1,416,000 after buying an additional 1,040 shares during the period. Avestar Capital LLC boosted its holdings in shares of Pfizer by 3.7% during the 3rd quarter. Avestar Capital LLC now owns 17,160 shares of the biopharmaceutical company’s stock worth $569,000 after buying an additional 606 shares during the period. Finally, Lake Street Financial LLC boosted its holdings in Pfizer by 22.3% in the 3rd quarter. Lake Street Financial LLC now owns 55,021 shares of the biopharmaceutical company’s stock valued at $1,766,000 after purchasing an additional 10,047 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Trading Up 0.2 %

Shares of PFE stock traded up $0.05 during mid-day trading on Tuesday, hitting $25.69. The company’s stock had a trading volume of 13,712,527 shares, compared to its average volume of 41,659,465. The company’s fifty day simple moving average is $26.92 and its 200-day simple moving average is $28.31. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a market cap of $145.47 billion, a PE ratio of 71.50, a P/E/G ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the company posted $1.14 EPS. The business’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.54%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.